Veterinary Clinical Reference
Look up any drug or condition.
Evergreen, evidence-based hubs on the drugs, conditions, and species you manage — continuously updated and cited at every claim.
Cannabidiol (CBD) for Canine Idiopathic Epilepsy: What the Controlled Trials Show
Two randomized trials and a pilot cohort show CBD added to antiseizure drugs modestly cuts seizure frequency in dogs, but not the 50%-responder rate; ALP rises consistently, so monitor the liver and watch CYP450 interactions.
Read →Zonisamide for Canine Idiopathic Epilepsy: Efficacy, Tolerability, and Therapeutic Drug Monitoring
Evidence review for veterinarians: a 207-dog TDM cohort proposes a 10-55 mcg/mL canine reference interval and 76% of newly-diagnosed dogs reached >=50% seizure reduction on monotherapy, with feline tolerability signals from a 57-cat cohort.
Read →Levetiracetam for Canine Idiopathic Epilepsy: Comparative Outcomes, Serum Monitoring, and Intranasal Emergency Use
Evidence review of levetiracetam for canine idiopathic epilepsy: outcomes similar to zonisamide and phenobarbital with fewer adverse effects, the phenobarbital serum interaction, intranasal emergency PK, and the class-level weight-gain effect. Includes rTMS and metabolic adjuncts for drug-resistant cases.
Read →Omeprazole and Gastroprotectants in Dogs: ACVIM Consensus, Overprescription Evidence, and Drug Interactions
Evidence-based review for DVMs: the 2018 ACVIM consensus reshaped omeprazole prescribing, yet a 265-vet survey shows persistent overprescription; long-term use raises gastrin without cobalamin change, and the feline clopidogrel interaction is PK-real but PD-limited.
Read →Enflicoxib (Daxocox) for Canine Osteoarthritis: A Once-Weekly COX-2 Selective NSAID
Enflicoxib (Daxocox) is an EU-authorised, once-weekly COX-2 selective NSAID for canine osteoarthritis. This hub reviews its mechanism, 6-month field efficacy and safety (Salichs 2024), long-term durability, comparators, and clinical placement.
Read →Lokivetmab (Cytopoint) for Canine Atopic Dermatitis: IL-31 Targeting and Clinical Evidence
Lokivetmab (Cytopoint) neutralizes IL-31 to control pruritus in canine atopic dermatitis. Evergreen review of pivotal RCTs, 12-month durability, ciclosporin comparison, COLT combination therapy, and the 2024-2025 JAK-inhibitor landscape.
Read →Potassium Bromide (KBroVet) for Canine Idiopathic Epilepsy: FDA Full Approval, Dosing, and Monitoring
KBroVet (potassium bromide) received FDA full approval in January 2026 for canine idiopathic epilepsy. A clinical reference on mechanism, dosing, pharmacokinetics, bromism, and the real-world serum-monitoring gap (31.6% for bromide vs 77.5% for phenobarbital).
Read →Fluralaner (Bravecto) for Canine Generalized Demodicosis: Field Study Evidence
Two controlled studies confirm 98–100% mite-free rates with a single fluralaner administration for canine generalized demodicosis, outperforming imidacloprid/moxidectin — with 2026 data extending single-dose cure to sarcoptic mange and reviews refining the isoxazoline MDR1 neurologic-safety signal.
Read →Trilostane (Vetoryl) for Canine Hyperadrenocorticism: Evidence and Monitoring
Trilostane (Vetoryl) inhibits 3β-HSD for canine hyperadrenocorticism, resolving PU/PD in 70% and skin changes in 62% of dogs. Emerging evidence favours pre-trilostane cortisol over the ACTH stimulation test for monitoring clinical control.
Read →Cyclosporine (Atopica) for Canine Atopic Dermatitis: Evidence and Use
Evidence-based guide to cyclosporine (Atopica/Cyclavance) for canine atopic dermatitis: RCT efficacy vs placebo and methylprednisolone, the ~4-week onset and prednisolone bridging strategy, long-term safety, vaccination planning, CYP3A4 interactions, and feline PK contrast.
Read →Imepitoin (Pexion) for Canine Idiopathic Epilepsy: Evidence Review
Evidence-based review of imepitoin (Pexion) for canine idiopathic epilepsy — pivotal RCT efficacy, its favourable adverse-event profile versus phenobarbital, PK, and the emerging off-label feline data.
Read →Oclacitinib (Apoquel) for Canine Atopic Dermatitis: JAK Inhibition and Clinical Evidence
Oclacitinib (Apoquel) for canine atopic dermatitis: 24-hour onset RCT data, head-to-head vs prednisolone, ciclosporin, and ilunocitinib, 10-year safety and neoplasia evidence, JAK1 mechanism, combination protocols, and monitoring.
Read →